Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“A new prospective cohort study on survival outcomes with or without bilateral risk-reducing mastectomy (BRRM) in BRCA1 and BRCA2 pathogenic variant carriers.
Key takeaways:
- BRRM reduced breastcancer annual incidence by ~94% (from 2.4% to 0.15%)
- However, breast cancer-specific OS was similar between BRRM and surveillance groups.
What does this mean for practice?
This remains a deeply personal, patient-centered decision. While surgery significantly lowers incidence, the reassuring survival outcomes for women who choose surveillance are important to acknowledge. For many patients, knowing that careful imaging follow-up does not appear to compromise survival may support more individualized, evidence-based choices.”
Title: Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
Authors: Ashu Gandhi, Sacha J. Howell, Elaine F. Harkness, Emma Woodward, Fiona Lalloo, Claire Forde, James Harvey, Lyndsey Highton, Nicola Flaum, D. Gareth Evans.
Other articles featuring Giuseppe Caruso on OncoDaily.